Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment – Implications to its mechanism of action

Imatinib mesylate (IM) is the first developed protein kinase inhibitor and recently it has topped consumption rates among targeted and total anticancer drugs. Although there are indications that IM possesses cyto/genotoxic activities against normal non-target cells as well, there is a lack of inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajski, Goran, Gerić, Marko, Domijan, Ana-Marija, Golubović, Ivana, Garaj-Vrhovac, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921178/
https://www.ncbi.nlm.nih.gov/pubmed/31885482
http://dx.doi.org/10.1016/j.jsps.2019.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921178/
https://www.ncbi.nlm.nih.gov/pubmed/31885482
http://dx.doi.org/10.1016/j.jsps.2019.10.005

Ejemplares similares